Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03353532
Other study ID # SALT
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2017
Est. completion date January 31, 2021

Study information

Verified date May 2021
Source University of Cologne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a retrospective multinational, multicenter cohort study with a nested case-control. The study includes all surgical procedures performed at a participating site to prevent bias. Data will be assessed in two populations. Cohort population: Export of electronic file data on demographics, surgical procedure ICPM code, duration of procedure, American Society of Anesthesiologists (ASA) score, body mass index, comorbidity ICD codes, and wound class of all patients undergoing surgery. Nested case-control population: For patients establishing S. aureus SSI and 1:1 matched controls from the same center further data will be captured: Length of hospitalization, length of ICU stay and reason as well as attribution to SSI, survival at 30 and at 90 days, antibiotic treatments including duration, functional status at admission and at final discharge; necessity for surgical revision, and death attributed to SSI. If readmission is necessary, reason and attribution to SSI, length of hospitalization and length of ICU stay as well as all antibiotic treatments and their duration will be recorded. The cases causative pathogens including resistance patterns and type of SSI according to CDC criteria will be captured. Matching criteria comprise the following: - Type of procedure - Age - ASA score - BMI - Duration of procedure (as percentile for this procedure) - Diabetes - Sex


Recruitment information / eligibility

Status Completed
Enrollment 178902
Est. completion date January 31, 2021
Est. primary completion date January 1, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years at the time of surgery Exclusion Criteria: - Cases with missing data defined as "missing completely at random" (MCAR) - Infection at the time of surgery

Study Design


Locations

Country Name City State
France Centre Hospitalier Départemental Vendee La Roche-sur-Yon
France Centre Hospitalier et Universitaire de Limoges Limoges
France Centre Hospitalier Régional et Universitaire de Tours Tours
Germany University Hospital Bonn Bonn
Germany University Hospital Cologne Cologne NRW
Germany Jena University Hospital Jena
Germany Hospital of the University of Munich Munich
Italy University of Udine and Azienda Sanitaria Universitaria Integrata Udine
Spain Hospital Clínic Barcelona Barcelona
Spain Institut Hospital del Mar d'Investigacions Mèdiques Barcelona
Spain Hospital General Universitario Gregorio Marañón e Instituto de Investigación Sanitaria Gregorio Marañón Madrid
Spain Hospital Universitario Ramón y Cajal Madrid
Spain Hospital Universitari i Politècnic La Fe Valencia
United Kingdom Manchester University NHS Foundation Trust (MFT) Manchester

Sponsors (2)

Lead Sponsor Collaborator
University of Cologne Pfizer

Countries where clinical trial is conducted

France,  Germany,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other To characterize the composition of the surgical patient population in Europe The composition of the surgical patient population in Europe will be performed by subgroup Analysis of the cohort 30 days from surgical procedure
Other To estimate the number of patients at risk for Staphylococcus aureus surgical site infection This will be extrapolated from epidemiologcal data assessed within the cohort 30 days from surgical procedure
Other To estimate the economic burden, including direct treatment and indirect costs, imposed by Staphylococcus aureus surgical site infections in Europe Direct and indirect Treatment costs will be assessed within the case-control part. Cases and controls will be compared regarding costs. 30 days from surgical procedure
Primary To determine overall incidence of Staphylococcus aureus surgical site infections in Europe Surgical site infections will be determined within the cohort of all patients that underwent surgery within 1 year at all participating sites. 30 days from surgical procedure
Primary To determine procedure specific incidence of Staphylococcus aureus surgical site infections in Europe Surgical site infections will be determined within the cohort of all patients that underwent surgery within 1 year at all participating sites. A subgroup Analysis will reveal procedure specific incidence. 30 days from surgical procedure
Secondary To determine the overall outcomes of Staphylococcus aureus surgical site infections in Europe The Outcome will be assessed within the case-control part and achieved by comparison of Overall Outcome of cases and controls 30 days from surgical procedure
Secondary To determine the procedure specific outcomes of Staphylococcus aureus surgical site infections in Europe The Outcome will be assessed within the case-control part and achieved by comparison of procedure specific Outcome of cases and controls 30 days from surgical procedure
Secondary To determine the overall economic burden of Staphylococcus aureus surgical site infections in Europe The economic burden will be assessed within the case-control part and achieved by comparison of Overall economic burden (i.e. ICU Treatment, hemodialysis and mechanical Ventilation) of cases and controls 30 days from surgical procedure
Secondary To determine the procedure specific economic burden of Staphylococcus aureus surgical site infections in Europe The economic burden will be assessed within the case-control part and achieved by comparison of procedure specific economic burden (i.e. ICU Treatment, hemodialysis and mechanical Ventilation) of cases and controls 30 days from surgical procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05073926 - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Completed NCT01212120 - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections N/A
Completed NCT00801879 - Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection Phase 4
Terminated NCT03638947 - Reducing Perioperative S. Aureus Transmission N/A
Recruiting NCT05331885 - A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 Phase 3
Recruiting NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Phase 4
Not yet recruiting NCT05092464 - Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis N/A
Recruiting NCT05695196 - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant Phase 1
Enrolling by invitation NCT04666532 - S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
Active, not recruiting NCT02572791 - Staph Household Intervention for Eradication (SHINE) Phase 4
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT01011335 - Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial Phase 1/Phase 2
Completed NCT03816956 - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 Phase 3
Not yet recruiting NCT04884958 - A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
Completed NCT01105767 - Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees N/A
Completed NCT00475930 - Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates N/A
Completed NCT00507247 - Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Phase 2
Recruiting NCT03220386 - Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making N/A
Completed NCT03140423 - Mupirocin-Iodophor ICU Decolonization Swap Out Trial Phase 4